Nama's AI scorecard currently rates Roivant Sciences Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ROIV report earnings?

Roivant Sciences's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.45.

What is the ROIV price target?

The median analyst price target from 11 analysts is $51.00, with a range of $41.00 – $62.00.

Is ROIV Shariah compliant?

Nama's AAOIFI-style screen reads Roivant Sciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Roivant Sciences (ROIV)

Healthcare · Biotechnology · NASDAQ

Roivant Sciences (ROIV) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $28.08B and a free-cash-flow yield of -3.5%. Over the most recent reported fiscal year, revenue declined 71.6%. Nama's AI scorecard rates it Sell, 3.1 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +68.9% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-8.5%

How far the last close sits under the highest price of the past five years.

Market cap	$28.08B
Trailing P/E	—
Price / book	6.6
Price / sales	3888.0
FCF yield	-3.5%
Dividend yield	—
Gross margin	81.2%
Operating margin	-18146.1%
Net margin	-3535.0%
Revenue growth (YoY)	-71.6%
Revenue growth (3-yr annual)	-36.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ROIV earnings

Next report: Nov 9, 2026 (Q2 2027, EPS estimate -$0.45). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2027	Aug 6, 2026	-$0.34	-$0.36	+5.6%	$1.44M
Q4 2026	May 20, 2026	-$0.32	-$0.35	+8.6%	$2.52M
Q3 2026	Feb 6, 2026	-$0.24	-$0.31	+22.6%	$2.00M
Q2 2026	Nov 10, 2025	-$0.28	-$0.30	+6.7%	$1.57M

ROIV analyst price target

Median target $51.00 from 11 analysts, ranging $41.00 – $62.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ROIV data on Nama Insights →

Recent Congressional trades

Roivant Sciences trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025

ROIV FAQ

Is ROIV a buy?: Nama's AI scorecard currently rates Roivant Sciences Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ROIV report earnings?: Roivant Sciences's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.45.
What is the ROIV price target?: The median analyst price target from 11 analysts is $51.00, with a range of $41.00 – $62.00.
Is ROIV Shariah compliant?: Nama's AAOIFI-style screen reads Roivant Sciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.